Benedict Financial Advisors Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,723 shares of the medical research company’s stock after acquiring an additional 377 shares during the period. Amgen comprises approximately 2.1% of Benedict Financial Advisors Inc.’s portfolio, making the stock its 14th largest position. Benedict Financial Advisors Inc.’s holdings in Amgen were worth $4,095,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of AMGN. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Amgen in the first quarter worth $110,402,000. Swiss National Bank grew its stake in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after acquiring an additional 551,600 shares in the last quarter. Bank of Nova Scotia grew its stake in shares of Amgen by 414.4% in the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after acquiring an additional 484,868 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Amgen by 37.4% in the first quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock worth $236,775,000 after acquiring an additional 392,538 shares in the last quarter. Finally, Morningstar Investment Services LLC grew its stake in shares of Amgen by 283.8% in the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after acquiring an additional 367,894 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.
Shares of Amgen Inc. (AMGN) opened at 185.79 on Wednesday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The stock has a 50 day moving average of $182.35 and a 200-day moving average of $170.56. The stock has a market capitalization of $135.57 billion, a PE ratio of 16.92 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period last year, the firm posted $2.84 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.19% of the company’s stock.
Several research firms have commented on AMGN. UBS AG restated a “neutral” rating and issued a $175.00 price target (up previously from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. Morgan Stanley boosted their price target on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Royal Bank Of Canada initiated coverage on shares of Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price objective for the company. Ten investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $189.99.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.